If validated, the findings could inform strategies for improving responses to BRAF/MEK inhibitors including using androgen receptor blockers.
The firm envisions marketing the 53-gene signature with its existing MammaPrint and BluePrint tests as a comprehensive platform for breast cancer treatment selection.
The first test of its radiopharmaceutical technology will be in PSMA-positive prostate cancer, which is poised to enter the clinic later this year.
The LUMINA trial showed that a molecularly defined subset of breast cancer patients over age 55 had an extremely low local recurrence rate when they omitted radiation.
The targeted agents significantly improved response rates and survival times versus upfront chemotherapy for BRAF V600E-mutant pediatric low-grade glioma patients.
At ASCO, two sub-studies from the Phase III VISION trial shed light on which prostate cancer patients are likely to benefit most from Novartis' targeted radionuclide.
Researchers at ASCO shared data pointing to gene amplification, protein overexpression, and TP53 mutations as biomarkers for identifying best responders to adavosertib.
Two studies presented Friday suggested that biomarker-selected approaches could improve patient outcomes on immunotherapy and targeted therapy.
Investors were unimpressed last week with the data they saw, though the company tried to reassure them that the findings were positive given the refractory population.
The study, conducted at the University of Southampton, homed in on crown-like structures of immune cells on the border of body fat and tumor tissue as a biomarker for anti-HER2 drug response.